Search clinical trials for: HR positive

Total 34250 results

Ding Ma

Recruiting

Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women

Cervical Cancer | HPV Infection

China
Intima Bioscience, Inc.

Not yet recruiting

CISH Inactivated TILs in the Treatment of NSCLC (CheckCell-2)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Large Cell Lung Cancer

United States
Immunitas Therapeutics

Recruiting

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Follicular Lymphoma | Colorectal Cancer | Hodgkin Lymphoma | Esophageal Cancer | Small Bowel Cancer | Burkitt Lymphoma | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Diffuse Large B Cell Lymphoma | Head and Neck Squamous Cell Carcinoma | Hormone Receptor Positive Breast Carcinoma | Cutaneous...

United States
National Taipei University of Nursing and Health...
Ministry of Science and Technology, Taiwan; Chang Gung Children's Hospital

Recruiting

Board Game Project for Adolescents With Tourette Syndrome

Depression | Tourette Syndrome in Adolescence | Mental Health Issue | Social Adjustment

Taiwan
Telix International Pty Ltd

Recruiting

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Soft Tissue Sarcoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Glioblastoma Multiforme | Non Small Cell Lung Cancer | Cholangiocarcinoma | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
Monte Rosa Therapeutics, Inc

Recruiting

Study of Oral MRT-2359 in Selected Cancer Patients

NSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast Cancer

United States, Canada
Mayo Clinic

Recruiting

Blood-Based Biomarkers to Inform Treatment and Radiation Therapy Decisions for HPV Associated Oropharyngeal Squamous Cell Head and Neck Cancers

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Oropharyngeal Human Papillomavirus-Positive Squamous...

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) (TEDITUB)

Tuberculosis | Multidrug Resistant Tuberculosis

France
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Non-small Cell Lung Cancer
Samsung Medical Center

Recruiting

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Lung Adenocarcinoma

Korea, Republic of
University of California, Irvine

Recruiting

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

CAR-T Cell | Ph Positive ALL | Dasatinib

China
The Affiliated Hospital of Qingdao University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Breast Cancer
Hebei Medical University Fourth Hospital

Not yet recruiting

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Solid Tumor
Olema Pharmaceuticals, Inc.
Novartis

Recruiting

Phase 1b Combo w/ Ribociclib and Alpelisib

Advanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast Cancer

United States, Australia
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III | Lung Adenocarcinoma Stage IV

China
Celcuity, Inc.

Recruiting

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1)

Breast Cancer

Korea, Republic of, United States, Belgium, United Kingdom, Taiwan, France, Italy, Australia, Singapore, Argentina, Canada, India, Mexico, Czechia, Spain, Austria, Bulgaria, Germany, Hungary, Poland, Brazil, Greece, Romania
Peking Union Medical College Hospital
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Carcinoma, Non-Small-Cell Lung | Anaplastic Lymphoma Kinase I1171N | Ensartinib

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Oropharyngeal Cancer | HPV | Human Papilloma Virus | Throat Cancer | Oropharyngeal Carcinoma

United States
Sun Yat-sen University
The First Affiliated Hospital with Nanjing Medical University; Second Affiliated... and other collaborators

Not yet recruiting

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Non-Small Cell Lung Cancer

China
PT Bio Farma
Hasan Sadikin General Hospital

Not yet recruiting

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)

Diphtheria Vaccine Adverse Reaction | Tetanus Vaccine Adverse Reaction | Pertussis Vaccine Adverse Reaction | Haemophilus Influenzae Type B Vaccine Adverse Reaction | Hepatitis B Vaccine Adverse Reaction

Indonesia
Konkuk University Medical Center
Yuhan Corporation

Recruiting

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Non Small Cell Lung Cancer

Korea, Republic of
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Collin Blakely
Novartis

Recruiting

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer

United States
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer

Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Advanced Breast Cancer

China
wang shusen

Recruiting

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Breast Cancer

China
Hebei Medical University

Not yet recruiting

Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
Peking University Cancer Hospital & Institute

Recruiting

A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

HR-positive,HER2-negative in Advanced Breast Cancer

China
Southwest Oncology Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

Hormone Receptor Positive Advanced Breast Cancer

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer

EGFR/ B7H3-positive Advanced Lung Cancer | EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sung Yong Lee
Yuhan Corporation

Recruiting

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

Non-small Cell Lung Cancer Stage III | Non-squamous Non-small-cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI); CytoImmune Therapeutics

Recruiting

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Melanoma | Sarcoma | Acute Myeloid Leukemia | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Stage III Pancreatic... and other conditions

United States
Miquel Angel Pavon Ribas
Catalan Institute of Health; Hospital del Mar

Recruiting

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV) (RIFT-HPV)

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) | Human Papillomavirus (HPV) Infections | High-risk HPV | HPV-16/ 18

Spain
Henan Cancer Hospital

Recruiting

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

HR Positive HER2 Negative Advanced Breast Cancer

China
Taizhou EOC Pharma Co., Ltd.

Not yet recruiting

HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy

Solid Tumor, Adult
N.N. Blokhin National Medical Research Center of...

Recruiting

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy (TRUST)

Non Small Cell Lung Cancer | EGFR Gene Mutation | T790M

Russian Federation
Second Affiliated Hospital, School of Medicine,...

Recruiting

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

Breast Cancer | Chemotherapeutic Toxicity

China
Regor Pharmaceuticals Inc.

Recruiting

First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Breast Cancer

United States
German Breast Group
Roche Pharma AG

Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (GeparPiPPa)

HER2-positive Breast Cancer

Germany
Amsterdam UMC, location VUmc

Recruiting

Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors (COMBINATION)

Non-Small Cell Lung Cancer

Netherlands
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States

Search clinical trials for: HR positive

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations